156P Systemic therapy effectiveness in metastatic non-uterine leiomyosarcoma: A decade of real-world outcomes from an Indian cohort

Key Points

To evaluate the effectiveness and safety of cabozantinib in patients with metastatic non-uterine leiomyosarcoma.
Retrospective cohort analysis of 16 patients
Assessment of survival outcomes including PFS and overall survival
QoL measured using the EORTC QLQ-C30 at baseline and 3 months
Mutation analysis to identify primary and secondary mutations
3-month overall response rate (ORR) was 20.0%
Median progression-free survival (PFS) was 4.0 months
Grade 3 adverse events included hand-foot skin reaction (20%) and hypertension (20%)
Quality of life showed non-significant worsening in several areas.

Real-world outcomes report cabozantinib's effectiveness in metastatic non-uterine leiomyosarcoma, indicating potential for further evaluation.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Shah et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share